Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
President and CEO of Enliven Therapeutics NASDAQ:ELVN, Samuel Kintz, sold 2,800 shares of common stock on September 23, 2025, at a price of $20.03, for a total value of $56,084. According to InvestingPro data, the stock appears overvalued at current levels, with analysts setting price targets between $33 and $52.
Following the transaction, Kintz indirectly holds 919,092 shares through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.
The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024. InvestingPro analysis reveals additional insights about Enliven’s financial health, with 6 more exclusive tips available for subscribers.
In other recent news, Enliven Therapeutics has garnered attention following updates related to its promising cancer treatment, ELVN-001. The company recently presented updated results from its Phase 1a/1b ENABLE trial at the EHA 2025, focusing on patients with chronic myelogenous leukemia. These developments have led H.C. Wainwright to raise its price target for Enliven Therapeutics from $40 to $48, while maintaining a Buy rating on the stock. Similarly, BTIG has reiterated its Buy rating with a price target of $45, emphasizing the potential of ELVN-001 as a next-generation tyrosine kinase inhibitor in the market for chronic myeloid leukemia. These analyst ratings reflect optimism about the efficacy and safety profile of ELVN-001. Enliven Therapeutics continues to make strides in its research, drawing positive attention from the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.